Covaxin 77.8% Effective Against Covid-19, 65.2% Against Delta Variant: Lancet Study
3 years, 1 month ago

Covaxin 77.8% Effective Against Covid-19, 65.2% Against Delta Variant: Lancet Study

News 18  

Covaxin, a Covid-19 vaccine developed by Hyderabad-based Bharat Biotech, was found to have a 77.8% efficacy rate against symptomatic Covid-19, as per an analysis published in The Lancet. The roll-out of Covaxin can “increase the finite global manufacturing capacity, and improve the insufficient supply of vaccines which disproportionately affects low-income and middle-income countries”, said Chinese researchers Li Jingxin Li and Zhu Fengcai, who did not take part in the study. Since then more than 100 million doses of Covaxin have been deployed across India and last week the World Health Organization added the inoculation to its list of Covid vaccines authorized for emergency use. Defending the vaccine, Bharat Biotech CMD Krishna Ella while speaking at Times Now summit said that the delay in granting the EUA by the World Health Organisation for Covaxin, was to be blamed on the “negative campaign” against the vaccine in India.

India Covid Delta Vaccine Bharat Biotech Lancet Covaxin  variant  study  778  vaccine  lancet  652  india  efficacy  covid19  health  protection  delta  covaxin  variants  vaccines  effective  world

History of this topic

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccin
1 month, 1 week ago

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccin

Live Mint  

MUMBAI, India & HYDERABAD, India – Business Wire India PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational protein design, is pleased to announce that it has been selected for inclusion in the U.S. Government’s Project NextGen. As part of this initiative, the National Institute of Allergy and Infectious Diseases, part of the …

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine
3 months, 3 weeks ago

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine

Hindustan Times  

In a recent development, Hyderabad-based Indian Immunologicals Ltd in collaboration with Griffith University in Australia has made a significant breakthrough in COVID-19 vaccination technology. Indian Immunologicals Ltd unveils first needle-free booster vaccine “This accomplishment signifies a major step forward in our battle against COVID-19. According to the press release, the innovative vaccine sports an attenuated formulation that uses advanced codon …

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

Does frequently updating COVID-19 vaccines have any benefits? | Explained
10 months, 1 week ago

Does frequently updating COVID-19 vaccines have any benefits? | Explained

The Hindu  

Researchers update the composition of influenza vaccines every six months to match the strains of the virus that are circulating in the wild, so that the shots may provide protective immunity against the flu. The VE of COVID-19 vaccines varies according to the disease’s progression as well as the circulating strains. Thus, researchers worldwide rushed to revise COVID-19 vaccines that …

IISc comes up with warm vaccine against current strains of SARS-CoV-2
11 months, 2 weeks ago

IISc comes up with warm vaccine against current strains of SARS-CoV-2

The Hindu  

A heat-tolerant vaccine developed by the Indian Institute of Science researchers is said to be effective against all current strains of SARS-CoV-2 besides having the potential to be quickly adapted for future variants as well. According to IISc-Bengaluru, since the beginning of the COVID-19 pandemic, Prof. Raghavan Varadarajan from the institute’s Molecular Biophysics Unit and collaborators have been working on …

New COVID variant JN.1: Health Ministry says no need for booster dose
1 year ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

Updated COVID vaccines will be available later this week, recommended for everyone six months and up
1 year, 3 months ago

Updated COVID vaccines will be available later this week, recommended for everyone six months and up

Salon  

A new, fourth round of COVID-19 booster shots was approved Tuesday, following the recommendation of federal health agencies, which will make the vaccines available to Americans later this week. The Centers for Disease Control and Prevention followed suit this afternoon, with CDC director Mandy Cohen recommending updated vaccination for "everyone 6 months and older to better protect you and your …

Scientists inch closer to Covid vaccine that provides lifelong protection
1 year, 7 months ago

Scientists inch closer to Covid vaccine that provides lifelong protection

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Scientists have shown that a new Covid vaccine provides more durable …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

Covovax to be available on CoWIN as booster dose soon. Check details
1 year, 8 months ago

Covovax to be available on CoWIN as booster dose soon. Check details

Hindustan Times  

In view of rising cases of COVID-19 in various parts of the country, Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute’s Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. According to an official source, Singh had mentioned in his letter to the ministry that …

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults
1 year, 8 months ago

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults

Hindustan Times  

Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India on March 27, they said. …

Centre rolls out first nasal Covid vaccine as booster
1 year, 10 months ago

Centre rolls out first nasal Covid vaccine as booster

Hindustan Times  

India on Thursday rolled out the first nasal vaccine against Covid-19, to be administered as a primary or booster dose for adults, potentially widening the pool of people who may take a third vaccine against the infection, cutting tertiary costs, and easing pressures on supply and storage networks. “Being the world’s first intranasal Covid-19 vaccine, this marks a glorious tribute …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla
1 year, 11 months ago

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla

Firstpost  

Pune: Chief Executive Officer of Serum Institute of India, Adar Poonawalla, has said their Covovax vaccine will get approval as a booster dose against Covid-19 in the next 10 to 15 days. Poonawalla told the media that the vaccine works very well against the Omicron variant of coronavirus. Speaking to reporters on the sidelines of an event at the Bharati …

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study
1 year, 11 months ago

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study

News 18  

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the …

No second Covid-19 booster dose required: Report
1 year, 11 months ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

Can Your Vaccine Protect You Against BF.7? India Isolates New Strain, Begins Study to Test Efficacy
1 year, 11 months ago

Can Your Vaccine Protect You Against BF.7? India Isolates New Strain, Begins Study to Test Efficacy

News 18  

A sample of SARS-CoV-2 virus containing the BF.7, a sub-lineage of the Omicron variant, has successfully been isolated by India to assess the efficacy of available vaccines. “Scientists are studying whether the currently available vaccines are effective in preventing infections or serious illness caused by the new sub-variant,” a source was quoted as saying. India has reported at least four …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
1 year, 11 months ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
1 year, 11 months ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Staying prepared: On scaling up the pace of COVID-19 genome sequencing
1 year, 11 months ago

Staying prepared: On scaling up the pace of COVID-19 genome sequencing

The Hindu  

Three years after strict enforcement of its Zero-COVID strategy, China abandoned it abruptly, leading to a jump in cases each day — an estimated 250 million people were infected in 20 days in December, according to the media, overwhelming hospitals and crematoria. Though this variant was found in many countries, including India, months ago, there is fear that the uncontrolled …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
1 year, 11 months ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

More vaccine choices: The Hindu Editorial on Bharat Biotech’s intranasal COVID-19 vaccine
2 years ago

More vaccine choices: The Hindu Editorial on Bharat Biotech’s intranasal COVID-19 vaccine

The Hindu  

Nearly three months after Bharat Biotech’s intranasal COVID-19 vaccine was granted emergency use approval for primary vaccination of adults, the vaccine has now been given emergency use approval as a heterologous booster in adults over 18 years. As in the case of the intranasal vaccine for primary vaccination, the booster dose too was tested only for safety and immunogenicity, but …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

COVID-19 vaccines offer significant protection against reinfection: Study
2 years, 1 month ago

COVID-19 vaccines offer significant protection against reinfection: Study

India TV News  

COVID-19 vaccine: A recent study revealed that people earlier infected with the SARS-CoV-2 virus still benefit from vaccination against COVID-19, gaining 60% to 94% protection against reinfection. “In our study, we find a significant vaccine effectiveness against SARS-CoV-2 reinfection, and this shows the importance of vaccination also for those who might be protected by natural immunity," said Katrine Finderup Nielsen …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

CORBEVAX offers better immunity as a heterologous booster shot
2 years, 2 months ago

CORBEVAX offers better immunity as a heterologous booster shot

Deccan Chronicle  

HYDERABAD: Heterologous booster shots have gained significance in light of the waning effect of vaccine doses, especially against different variants of the Covid-19 virus. There is an increase in the immune response to the administration of heterologous booster shots on two counts – first cellular immunity and second, neutralizing antibodies. Administering the CORBEVAX vaccine as a heterologous booster dose provides …

AstraZeneca Nasal Spray Vaccine for Covid-19 Suffers Setback in Early Trial
2 years, 2 months ago

AstraZeneca Nasal Spray Vaccine for Covid-19 Suffers Setback in Early Trial

News 18  

In a major setback, AstraZeneca and the University of Oxford’s joint trial for the nasal-spray version of the Nonreplicating viral vector vaccine against Covid-19 did not yield desired protection, reported Reuters on Tuesday. The University of Oxford said, “An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in …

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences
2 years, 3 months ago

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences

News 18  

India will soon roll out mRNA shots and intranasal vaccines, which will be available on CoWIN, and can be used as boosters against Covid-19. India’s first mRNA shot is only the third mRNA vaccine to be approved for Covid-19 in the world after Pfizer and Moderna. But mortality will be reduced.” Sharing a study of the intranasal vaccines under clinical …

What is a COVID-19 nasal vaccine?
2 years, 3 months ago

What is a COVID-19 nasal vaccine?

The Hindu  

Since the launch of its COVID-19 vaccine programme in early 2021, India has protected millions at home and abroad from the virus. The Hyderabad-based Bharat Biotech, the makers of Covaxin, has got an approval for its nasal vaccine from the Central Drugs Standard Control Organisation. It is for primary immunisation against COVID-19 in the 18-plus age group, for restricted use …

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval
2 years, 3 months ago

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval

The Hindu  

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine has been approved by Central Drugs Standard Control Organisation for primary immunization against COVID-19 in 18+ age group for restricted use in emergencies, Health Minister Mansukh Mandaviya tweeted on Tuesday. Dr. Krishna Ella, chairman and managing director, Bharat Biotech, said: “iNCOVACC will be a global game changer in intra-nasal vaccines technology and delivery …

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use
2 years, 3 months ago

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use

News 18  

Bharat Biotech has been given an emergency use authorisation by India’s drug regulator, the Drug Controller General of India, for its intranasal Covid-19 vaccine, Union Health Minister Dr Mansukh Mandaviya tweeted on Tuesday. Big Boost to India's Fight Against COVID-19!Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted …

Tackling the new variants
2 years, 4 months ago

Tackling the new variants

Hindustan Times  

The first redesigned coronavirus vaccine was approved for use this week when authorities in the United Kingdom cleared a Moderna dose that the company adapted to create immunity against the Omicron variant. The vaccine is a 50-50 formulation of Moderna’s 2020 product, designed on the Sars-CoV-2 variant that first spread around the world, and of a new dose developed using …

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
2 years, 4 months ago

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

Deccan Chronicle  

HYDERABAD: Bharat Biotech International Limited on Monday said its COVID-19 intranasal vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. Suchitra K Ella, Joint Managing Director, Bharat Biotech, …

COVID-19: Corbevax to be given as boosters at vaccination centres from today
2 years, 4 months ago

COVID-19: Corbevax to be given as boosters at vaccination centres from today

Live Mint  

Hyderabad based-Biological E Ltd 's recently approved heterologous Covid-19 vaccine Corbevax to be available as a booster dose on the COWIN App in both public and private vaccination centres from 12 August, the firm said on 11 August. The Union Health Ministry approved Corbevax as India's first heterologous COVID-19 booster shot for 18 years and above after the six months …

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday
2 years, 4 months ago

Corbevax Likely to be Available As Covid Booster Dose at Vaccination Centres from Friday

News 18  

Biological E. Ltd on Thursday said it has delivered 10 crore doses of its Covid-19 vaccine, Corbevax to the Centre so far which is expected to be available as a booster dose on the Cowin App in public and private vaccination centers from Friday. Corbevax was also approved by the Union Health Ministry as a heterologous Covid-19 booster dose under …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
2 years, 4 months ago

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

Deccan Chronicle  

New Delhi: The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, official sources said on Wednesday. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield …

Discover Related